Free tool
FAERS Monitor: Ingrezza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209241 or its brand name (Ingrezza, Valbenazine Tosylate). Reports on generic versions are filed under their own applications.
Reports
25,388
Serious
6,141
24% of reports
Hospitalization
3,548
Death reported
1,314
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,780
- somnolence2,504
- fatigue1,699
- tremor1,611
- tardive dyskinesia1,537
- fall1,149
- dizziness968
- death946
- drooling926
- dyskinesia904
- therapeutic product effect decreased893
- off label use697
- anxiety689
- hospitalisation672
- nausea641
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1,145 |
| 2018 | 3,935 |
| 2019 | 3,742 |
| 2020 | 4,036 |
| 2021 | 6,279 |
| 2022 | 1,723 |
| 2023 | 1,170 |
| 2024 | 1,124 |
| 2025 | 1,187 |
| 2026 | 1,047 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,028,771 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| droolingSignal | 926 | 128.1 | 119.6 | 101,036 |
| tardive dyskinesiaSignal | 1,537 | 47.7 | 45.4 | 66,458 |
| dyskinesiaSignal | 904 | 18.8 | 17.6 | 14,929 |
| therapeutic product effect decreasedSignal | 893 | 16.8 | 15.8 | 13,046 |
| somnolenceSignal | 2,504 | 10.4 | 10.0 | 21,252 |
| tremorSignal | 1,611 | 8.1 | 7.7 | 10,017 |
| hospitalisationSignal | 672 | 3.6 | 3.4 | 1,285 |
| fallSignal | 1,149 | 2.9 | 2.7 | 1,412 |
| anxietySignal | 689 | 2.0 | 1.9 | 352 |
| fatigue | 1,699 | 1.8 | 1.7 | 637 |
| drug ineffective | 2,780 | 1.7 | 1.7 | 949 |
| dizziness | 968 | 1.6 | 1.5 | 228 |
| death | 946 | 0.9 | 0.9 | 9 |
| nausea | 641 | 0.7 | 0.6 | 107 |
| off label use | 697 | 0.7 | 0.6 | 128 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.